TIGAR Deficiency Blunts Angiotensin-II-Induced Cardiac Hypertrophy in Mice
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25042433 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Xiaochen He und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, School of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA. Hauptthemen laut MEDLINE: Angiotensin II, Apoptosis Regulatory Proteins, Cardiomegaly, Hypertension. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Hypertension is the key contributor to pathological cardiac hypertrophy. Growing evidence indicates that glucose metabolism plays an essential role in cardiac hypertrophy. TP53-induced glycolysis and apoptosis regulator (TIGAR) has been shown to regulate glucose metabolism in pressure overload-induced cardiac remodeling. In the present study, we investigated the role of TIGAR in cardiac remodeling during Angiotensin II (Ang-II)-induced hypertension. Wild-type (WT) and TIGAR knockout (KO) mice were infused with Angiotensin-II (Ang-II, 1 µg/kg/min) via mini-pump for four weeks. The blood pressure was similar between the WT and TIGAR KO mice. The Ang-II infusion resulted in a similar reduction of systolic function in both groups, as evidenced by the comparable decrease in LV ejection fraction and fractional shortening. The Ang-II infusion also increased the isovolumic relaxation time and myocardial performance index to the same extent in WT and TIGAR KO mice, suggesting the development of similar diastolic dysfunction. However, the knockout of TIGAR significantly attenuated hypertension-induced cardiac hypertrophy. This was associated with higher levels of fructose 2,6-bisphosphate, PFK-1, and Glut-4 in the TIGAR KO mice. Our present study suggests that TIGAR is involved in the control of glucose metabolism and glucose transporters by Ang-II and that knockout of TIGAR attenuates the development of maladaptive cardiac hypertrophy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, School of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA.
ORCID-Profile: Xiaochen He, Aubrey C Cantrell, Jian-Xiong Chen
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
He, X., Williams, Q. A., Cantrell, A. C., Besanson, J., Zeng, H., & Chen, J. X. (2024). TIGAR Deficiency Blunts Angiotensin-II-Induced Cardiac Hypertrophy in Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25042433
Vancouver
He X, Williams QA, Cantrell AC, Besanson J, Zeng H, Chen JX. TIGAR Deficiency Blunts Angiotensin-II-Induced Cardiac Hypertrophy in Mice. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25042433
BibTeX
@article{He2024,
author = {He, Xiaochen and Williams, Quinesha A and Cantrell, Aubrey C and Besanson, Jessie and Zeng, Heng and Chen, Jian-Xiong},
title = {TIGAR Deficiency Blunts Angiotensin-II-Induced Cardiac Hypertrophy in Mice},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25042433}
}
EUVIMED